Symtomax Portugal, a medical cannabis operator, has announced that it has been granted approval to commence cultivation from INFARMED, the Portuguese regulatory authority for the pharmaceutical industry in Portugal.
Symtomax was established in 2017 with a commitment to advancing alternative and effective products to improve the health and well-being of people.
The license will allow Symtomax to develop into a vertically-integrated cannabis business, cultivating from both indoor and outdoor facilities, with future plans for R&D, to processing, packaging and distribution of medicinal cannabis oil and other cannabinoid-based products.
Cannabis remains illegal in most countries so please reference your local laws in relation to medical or recreational use.